Selank

Selank — Anxiolytic Tuftsin Analogue by Dragon Pharma

Selank is Dragon Pharma's formulation of the synthetic heptapeptide anxiolytic at 10mg per vial — a tuftsin analogue developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (Moscow) and registered as a pharmaceutical drug in Russia for anxiety and cognitive disorders. Selank produces anxiolytic and nootropic effects through BDNF upregulation and GABA-A receptor modulation — critically, without the sedation, dependence or cognitive impairment associated with benzodiazepines, which work through the same GABA system.

Also searched as: Selank 10mg, Selank peptide anxiety, tuftsin analogue anxiolytic, Selank Dragon Pharma.

What Selank Is — Origin and Development

Selank's origin distinguishes it from most performance peptides:

• Selank was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences — part of a broader Soviet/Russian programme into peptide bioregulators for neurological applications
• It is a synthetic analogue of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) found in the Fc region of IgG immunoglobulin. Tuftsin was originally identified as an immune system modulator; researchers extended the sequence and modified the structure to produce the heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) with enhanced stability and CNS activity
• Selank is registered as a pharmaceutical drug in Russia (registration number ЛС-000683) for the treatment of generalised anxiety disorder — making it one of the few peptides in the Dragon Pharma range with actual regulatory approval as a medicine, albeit in a non-Western jurisdiction
• Clinical trials in Russia established Selank's anxiolytic efficacy against placebo in patients with generalised anxiety disorder and neurasthenia — providing a clinical evidence base beyond animal studies

The Mechanism — BDNF and GABA-A Without Sedation

Understanding why Selank produces anxiety reduction without benzodiazepine-like side effects requires examining its specific mechanisms:

• BDNF upregulation: Selank significantly increases brain-derived neurotrophic factor (BDNF) — the primary growth factor supporting neuronal survival, synaptic plasticity and the formation of new neural connections. Reduced BDNF is consistently associated with anxiety disorders and depression; upregulating BDNF has been proposed as a mechanism of action for antidepressants. Selank's BDNF elevation is documented in animal and some human data
• GABA-A modulation: Selank modulates GABA-A receptor function — the same receptor system targeted by benzodiazepines (Valium, Xanax). However, Selank's mechanism at GABA-A is different from benzodiazepines: it acts as a positive allosteric modulator at specific subunits rather than binding the benzodiazepine site, producing anxiolytic effects without the sedation, cognitive impairment and physical dependence that benzodiazepine site agonism causes
• Serotonin system: Selank has demonstrated effects on serotonin metabolism — increasing serotonin turnover in brain regions associated with anxiety and mood regulation
• Enkephalin metabolism: Selank inhibits enkephalinase — the enzyme that breaks down natural opioid peptides (enkephalins). This prolongs the action of endogenous enkephalins, contributing to anxiolytic and mood-stabilising effects through the endogenous opioid system

Selank vs Benzodiazepines — The Critical Comparison

Selank vs Semax — The Russian Peptide Comparison

Selank is frequently compared to Semax — both are Russian-developed CNS peptides — but they have distinct profiles:

• Selank — primarily anxiolytic; reduces anxiety and stress without sedation; BDNF and GABA-A mechanism; most appropriate when anxiety management and mood stabilisation are the primary goal
• Semax — primarily nootropic and stimulating; ACTH analogue that increases dopamine and serotonin; enhances focus, cognitive performance and stress resilience through upregulation of neurotrophins. More stimulating in character than Selank
• The two are often combined: Selank for anxiety reduction and mood stabilisation; Semax for cognitive enhancement and stimulation — covering complementary aspects of mental performance

AAS Context — Why Selank Is Relevant for Cycle Users

Selank has specific relevance for AAS users that competitor content does not address:

• AAS cycles — particularly Trenbolone, high-dose testosterone, and oral compounds — frequently produce CNS side effects including increased aggression, anxiety, irritability and mood instability
• Trenbolone is particularly associated with neurological side effects through its direct CNS activity; high-dose testosterone cycles alter GABA-A receptor sensitivity through neurosteroid mechanisms
• Selank's anxiolytic and mood-stabilising effects through BDNF upregulation and GABA-A modulation provide a non-sedating countermeasure to cycle-induced CNS dysregulation — potentially reducing cycle-related anxiety and mood disturbance without the sedation that would impair training

Effects and Benefits

• Anxiety reduction without sedation — the defining clinical advantage over benzodiazepines
• BDNF upregulation — neuroprotective and cognitively enhancing alongside the anxiolytic effect
• Mood stabilisation — documented improvement in emotional stability in clinical trial populations
• Potential immune system modulation from the tuftsin base structure
• No physical dependence — no withdrawal syndrome on discontinuation
• No hormonal effects — no testosterone suppression, no PCT required

Dosage and Administration

Selank can be administered subcutaneously or intranasally — intranasal administration is particularly common in Russian clinical use and allows direct CNS delivery bypassing systemic circulation. At 10mg per vial and 500mcg per dose, one vial provides 20 doses. Reconstitute with bacteriostatic water. Store reconstituted vial refrigerated at 2-8°C for up to 28-30 days. Effects onset within 15-30 minutes of administration; duration approximately 4-6 hours.